Back to Trials
NCT05264051Recruiting

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

University of Chicago

Start Date

4/18/2022

Completion Date

3/1/2027

Summary

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

Detailed Description

Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each patient already undergoing MRI exam. Four groups of pts. who are already scheduled for MRI for routine clinical purposes will be evaluated. 1. Pts. hospitalized with acute hepatic decompensation for whom MRI is otherwise indicated for clinical evaluation. 2. Pts. with hepatobiliary neoplasia 3. Pts.undergoing transjugular portosystemic shunt (TIPS) placement 4. Pts. with chronic liver disease undergoing magnetic resonance elastography for routine monitoring

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated Exclusion Criteria: * \<18 yrs. of age

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Liver Diseases

Locations

The University of Chicago

Chicago, Illinois 60637

United States